UCB Pharma clinical trials

A subsidiary of UCB S.A.

The registry lists 276 studies whose lead sponsor is UCB Pharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 276. List all 276 → · All UCB S.A. studies →

• A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedNCT01521923Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedNCT01519791Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With EpilepsyCompletedNCT01364597Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseTerminatedNCT01519882Phase 4

  Sponsor listed in the registry: UCB Pharma SA

• To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using MethotrexateCompletedNCT01009242Phase 1/2

  Sponsor listed in the registry: UCB Pharma

• Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyCompletedNCT01242488Phase 2

  Sponsor listed in the registry: UCB Pharma

• A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).CompletedNCT00861068Phase 2

  Sponsor listed in the registry: UCB Pharma

• A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927CompletedNCT00800215Phase 2

  Sponsor listed in the registry: UCB Pharma

• A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic NeuropathyCompletedNCT00350103Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With EpilepsyCompletedNCT00150709Phase 3

  Sponsor listed in the registry: UCB Pharma

• An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic NeuropathyCompletedNCT00861042Phase 2

  Sponsor listed in the registry: UCB Pharma

• Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.CompletedNCT00546351Phase 3

  Sponsor listed in the registry: UCB Pharma

• Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking LevetiracetamCompletedNCT00152503Phase 2

  Sponsor listed in the registry: UCB Pharma SA

• A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic NeuropathyCompletedNCT00220337Phase 3

  Sponsor listed in the registry: UCB Pharma

• Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsCompletedNCT00368251Phase 3

  Sponsor listed in the registry: UCB Pharma

• Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset SeizuresCompletedNCT01261325Phase 3

  Sponsor listed in the registry: UCB Pharma

• Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresCompletedNCT00490035Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresCompletedNCT00464269Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung CancerCompletedNCT00152477Phase 2

  Sponsor listed in the registry: UCB Pharma

• Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine ChangesCompletedNCT00345800Phase 1

  Sponsor listed in the registry: UCB Pharma SA

• This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam TreatmentCompletedNCT00150800Phase 3

  Sponsor listed in the registry: UCB PHARMA Inc. (US)

• Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From EpilepsyCompletedNCT00175916Phase 3

  Sponsor listed in the registry: UCB Pharma

• Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset SeizuresCompletedNCT01832038Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) InhibitorsCompletedNCT01764321

  Sponsor listed in the registry: UCB Pharma SA

• Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab PegolCompletedNCT01190410Phase 2

  Sponsor listed in the registry: UCB Pharma

• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)CompletedNCT01261793Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00160602Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid ArthritisCompletedNCT00152386Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.CompletedNCT00175890Phase 3

  Sponsor listed in the registry: UCB Pharma

• Open Label Safety and Efficacy Study of Levetiracetam in Patients With EpilepsyCompletedNCT00160654Phase 4

  Sponsor listed in the registry: UCB Pharma

• Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's DiseaseCompletedNCT00291668Phase 2

  Sponsor listed in the registry: UCB Pharma

• Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset SeizuresCompletedNCT00615615Phase 3

  Sponsor listed in the registry: UCB Pharma

• Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized EpilepsyCompletedNCT00150748Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic RhinitisCompletedNCT00621959Phase 4

  Sponsor listed in the registry: UCB Pharma

• National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)CompletedNCT01095393

  Sponsor listed in the registry: UCB Pharma

• A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XRCompletedNCT00368069Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00160641Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00175877Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.CompletedNCT01969851Phase 2

  Sponsor listed in the registry: UCB Pharma

• Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque PsoriasisCompletedNCT00329303Phase 2

  Sponsor listed in the registry: UCB Pharma

• Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/PhotochemotherapyCompletedNCT00245765Phase 2

  Sponsor listed in the registry: UCB Pharma

• A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial SeizuresCompletedNCT00938431Phase 2

  Sponsor listed in the registry: UCB Pharma

• A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)CompletedNCT00160667Phase 2

  Sponsor listed in the registry: UCB Pharma

• Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)CompletedNCT00152464Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.CompletedNCT00150813Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044CompletedNCT02319642Phase 3

  Sponsor listed in the registry: UCB Pharma SA

• A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male SubjectsCompletedNCT01710670Phase 1

  Sponsor listed in the registry: UCB Pharma SA

• Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus ErythematosusCompletedNCT01408576Phase 3

  Sponsor listed in the registry: UCB Pharma

• A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.CompletedNCT00175825Phase 2

  Sponsor listed in the registry: UCB Pharma

• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus ErythematosusCompletedNCT01262365Phase 3

  Sponsor listed in the registry: UCB Pharma